Merck revenue rises 1% YoY to $12.6B in Q3

Tuesday, 27. October 2020 11:56

American pharmaceutical company Merck & Co., Inc. said on Tuesday its third-quarter earnings increased 1% to $12.6 billion. The figure came in above expectations.

Meanwhile, earnings per share during the same period landed at $1.16, up 57% compared to the third quarter of 2019. Among other highlights from Merck's earnings report, the company noted sales for Keytruda, its antibody treatment used in cancer immunotherapy, jumped 21% to $3.7 billion.

"We continue to execute on our strategic priorities and remain confident we will achieve solid full-year revenue growth despite the impact of the ongoing COVID-19 pandemic. Demand for our products remains robust, and production, supply and distribution of our medicines, vaccines and animal health products are moving forward with minimal disruption," CEO Kenneth C. Frazier commented on the results.

Shares of Merck climbed 1.32% to $79.88 in premarket trading after the earnings announcement.

Related Links: Merck & Co. Inc.
Breaking the News / JC